Sunanda V. Kane, M.D.

  1. Gastroenterologist
  2. Internist

Publications

  1. Mahadevan U, Robinson C, Bernasko N, Boland B, Chambers C, Dubinsky M, Friedman S, Kane S, Manthey J, Sauberan J, Stone J, Jain R. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology. 2019 Apr; 156 (5):1508-1524 Epub 2019 Jan 16
    View PubMed
  2. Mahadevan U, Robinson C, Bernasko N, Boland B, Chambers C, Dubinsky M, Friedman S, Kane S, Manthey J, Sauberan J, Stone J, Jain R. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. Am J Obstet Gynecol. 2019 Apr; 220 (4):308-323
    View PubMed
  3. Mahadevan U, Robinson C, Bernasko N, Boland B, Chambers C, Dubinsky M, Friedman S, Kane S, Manthey J, Sauberan J, Stone J, Jain R. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. Inflamm Bowel Dis. 2019 Mar 14; 25 (4):627-641
    View PubMed
  4. Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Kesar V, Lasch K, Luo M, Bohm M, Varma S, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Kane S, Loftus EV Jr, Sands BE, Colombel JF, Dulai PS, Ungaro R. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 Jan 6 Epub 2019 Jan 06
    View PubMed
  5. Ananthakrishnan AN, Martin C, Kane S, Sandler RS, Long MD. Paternal Disease Activity Is Associated With Difficulty in Conception Among Men With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 Jan; 17 (1):203-204 Epub 2018 Apr 11
    View PubMed
  6. Chaudrey K, Shmidt E, Singh S, Kane S, Loftus EV, Sandborn WJ. Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018 Dec; 113 (12):1912
    View PubMed
  7. Elia J, Kane S. Adult Inflammatory Bowel Disease, Physical Rehabilitation, and Structured Exercise. Inflamm Bowel Dis. 2018 Nov 29; 24 (12):2543-2549
    View PubMed
  8. Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M, Luo M, Lasch K, Boland BS, Singh S, Vande Casteele N, Sagi SV, Fischer M, Chang S, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Kane S, Loftus EV Jr, Sandborn WJ, Siegel CA, Sands BE, Colombel JF, Shen B, Dulai PS. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Oct 12; 24 (11):2461-2467
    View PubMed
  9. Aniwan S, Harmsen WS, Tremaine WJ, Kane SV, Loftus EV Jr. Overall and Cause-Specific Mortality of Inflammatory Bowel Disease in Olmsted County, Minnesota, From 1970 Through 2016. Mayo Clin Proc. 2018 Oct; 93 (10):1415-1422 Epub 2018 July 04
    View PubMed
  10. Meserve J, Aniwan S, Koliani-Pace JL, Shashi P, Weiss A, Faleck D, Winters A, Chablaney S, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Hartke JG, Chilukuri P, Bohm M, Sagi SV, Fischer M, Lukin D, Hudesman D, Chang S, Gao Y, Sultan K, Swaminath A, Gupta N, Kane S, Loftus EV Jr, Shen B, Sands BE, Colombel JF, Siegel CA, Sandborn WJ, Dulai PS. Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2018 Sep 27 Epub 2018 Sept 27
    View PubMed
  11. Kane S. Leter to the Editor. Inflamm Bowel Dis. 2018 Sep 7 Epub 2018 Sept 07
    View PubMed
  12. Kane SV, Chandrasekhara V, Sedlack RE, Buttar NS. Credentialing for Endoscopic Practice: The Mayo Clinic Model. Clin Gastroenterol Hepatol. 2018 Sep; 16 (9):1370-1373.e1 Epub 2018 June 18
    View PubMed
  13. Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018 Sep; 113 (9):1345 Epub 2018 June 27
    View PubMed
  14. Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P, Meserve J, Whitehead D, Hirten R, Winters AC, Katta LG, Peerani F, Narula N, Sultan K, Swaminath A, Bohm M, Lukin D, Hudesman D, Chang JT, Rivera-Nieves J, Jairath V, Zou GY, Feagan BG, Shen B, Siegel CA, Loftus EV Jr, Kane S, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Cao C. Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. Gastroenterology. 2018 Sep; 155 (3):687-695.e10 Epub 2018 May 30
    View PubMed
  15. McConnell RA, Kane SV. The Potential and Pitfalls of Using the Electronic Health Record to Measure Quality. Am J Gastroenterol. 2018 Aug; 113 (8):1111-1113 Epub 2018 June 11
    View PubMed
  16. Hansel SL, McCurdy JD, Barlow JM, Fidler J, Fletcher JG, Becker B, Prabhu NC, Faubion WA, Hanson KA, Kane SV, Kisiel JB, Loftus EV Jr, Papadakis KA, Pardi DS, Raffals LE, Schoenoff S, Tremaine WJ, Bruining DH. Clinical Benefit of Capsule Endoscopy in Crohn's Disease: Impact on Patient Management and Prevalence of Proximal Small Bowel Involvement. Inflamm Bowel Dis. 2018 Jun 8; 24 (7):1582-1588
    View PubMed
  17. Mouchli MA, Singh S, Boardman L, Bruining DH, Lightner AL, Rosen CB, Heimbach JK, Hasan B, Poterucha JJ, Watt KD, Kane SV, Raffals LE, Loftus EV Jr. Natural History of Established and De Novo Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis. Inflamm Bowel Dis. 2018 Apr 23; 24 (5):1074-1081
    View PubMed
  18. Mir FA, Kane SV. Health Maintenance in Inflammatory Bowel Disease. Curr Gastroenterol Rep. 2018 Apr 17; 20 (5):23
    View PubMed
  19. Bonthala N, Kane S. Updates on Women's Health Issues in Patients with Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2018 Mar; 16 (1):86-100
    View PubMed
  20. Kane S. Letter to the Editor: Missed Meals While Hospitalized for UC. Inflamm Bowel Dis 2018 Feb 15; 24 (3):660
    View PubMed
  21. Aniwan S, Tremaine WJ, Raffals LE, Kane SV, Loftus EV Jr. Antibiotic Use and New-Onset Inflammatory Bowel Disease in Olmsted County, Minnesota: A Population-Based Case-Control Study. J Crohns Colitis. 2018 Jan 24; 12 (2):137-144
    View PubMed
  22. Beaulieu DB, Ananthakrishnan AN, Martin C, Cohen RD, Kane SV, Mahadevan U. Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. Clin Gastroenterol Hepatol. 2018 Jan; 16 (1):99-105 Epub 2017 Sept 01
    View PubMed
  23. Hujoel IA, Rubio-Tapia A, Dao LN, Porrata LF, Kane SV. Epstein-Barr Virus-Positive Mucocutaneous Ulcer in an Immunosuppressed Patient. ACG Case Rep J. 2018; 5:e32 Epub 2018 Apr 25
    View PubMed
  24. Afzali A, Ciorba MA, Schwartz DA, Sharaf M, Fourment C, Ritter T, Wolf DC, Shafran I, Randall CW, Kane SV. Challenges in Using Real-world Clinical Practice Records for Validation of Clinical Trial Data in Inflammatory Bowel Disease: Lessons Learned. Inflamm Bowel Dis. 2017 Dec 19; 24 (1):2-4
    View PubMed
  25. Badshah MB, Walayat S, Ahmed U, Dhillon S, Yong S, Kane S, Thievanayagam S. Treatment of orofacial granulomatosis: a case report. J Med Case Rep. 2017 Oct 25; 11 (1):300
    View PubMed
  26. Blevins CH, Kane SV. Importance of Considering the Financial Cost in Assessing Quality of Care. Inflamm Bowel Dis 2017 Sep; 23 (9):E47-E48
    View PubMed
  27. Gaidos JKJ, Kane SV. Sexuality, Fertility, and Pregnancy in Crohn's Disease. Gastroenterol Clin North Am. 2017 Sep; 46 (3):531-546 Epub 2017 July 19
    View PubMed
  28. Martin T, Smukalla SM, Kane S, Hudesman DP, Greene R, Malter LB. Receptive Anal Intercourse in Patients with Inflammatory Bowel Disease: A Clinical Review. Inflamm Bowel Dis. 2017 Aug; 23 (8):1285-1292
    View PubMed
  29. Kane SV. Health Maintenance Assessment for Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2017 Aug; 13 (8):500-503
    View PubMed
  30. Visrodia K, Abu Dayyeh B, Kane S. Crohn's and a Cough: Connecting the Dots. Gastroenterology. 2017 Jul; 153 (1):21-22 Epub 2017 June 01
    View PubMed
  31. Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. Corrigendum: ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol. 2017 Jul; 112 (7):1208 Epub 2017 May 23
    View PubMed
  32. Kane S, Buttar N, Gleeson F, Larson M, Song LWK, Yates R. The Impact on Endoscopic Resource Utilization After A Targeted Intervention for Cost-Minimization of EGD and Colonoscopy. Am J Gastroenterol. 2017 Jun; 112 (6):968
    View PubMed
  33. Hilscher MB, Niesen CR, Tynsky DA, Kane SV. Pre-Procedural Patient Education Reduces Fall Risk in an Outpatient Endoscopy Suite. Gastroenterol Nurs. 2017 May/Jun; 40 (3):216-221
    View PubMed
  34. Gaidos JK, Kane SV. Managing IBD Therapies in Pregnancy. Curr Treat Options Gastroenterol. 2017 Mar; 15 (1):71-83
    View PubMed
  35. Keefer L, Kane SV. Considering the Bidirectional Pathways Between Depression and IBD: Recommendations for Comprehensive IBD Care. Gastroenterol Hepatol (N Y). 2017 Mar; 13 (3):164-169
    View PubMed
  36. Jin JJ, Keith PJ, Cummins NW, Kane SV, Pritt BS, Sanchez JL. Lysinibacillus massiliensis Panniculitis Masquerading as Erythema Nodosum: A Case Report. Open Forum Infect Dis. 2017 Spring; 4 (2):ofx072 Epub 2017 Apr 06
    View PubMed
  37. Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol. 2017 Feb; 112 (2):241-258 Epub 2017 Jan 10
    View PubMed
  38. Cross RK, Kane S. Integration of Telemedicine Into Clinical Gastroenterology and Hepatology Practice. Clin Gastroenterol Hepatol. 2017 Feb; 15 (2):175-181 Epub 2016 Dec 16
    View PubMed
  39. Parekh NK, Shah S, McMaster K, Speziale A, Yun L, Nguyen DL, Melmed G, Kane S. Effects of caregiver burden on quality of life and coping strategies utilized by caregivers of adult patients with inflammatory bowel disease. Ann Gastroenterol. 2017; 30 (1):89-95 Epub 2016 Sept 06
    View PubMed
  40. Patel B, Butterfield JH, Weiler CR, Kane SV. Tolerance and Efficacy with Simultaneous Use of Two Monoclonal Antibodies for a Patient with Hypereosinophilic Syndrome and Ulcerative Colitis. Monoclon Antib Immunodiagn Immunother. 2016 Dec; 35 (6):300-303 Epub 2016 Dec 02
    View PubMed
  41. Marshall AL, Zhang X, Lewis B, Kane S, Go RS. Sex-Based Disparities in the Use and Results of Gastrointestinal Procedures for Workup of Anemia Journal of Women’s Health, Issues & Care.2016;
  42. Kane SV. To the Editor. Inflamm Bowel Dis 2016 Nov; 22 (11):E42-E43
    View PubMed
  43. Gaidos JK, Kane SV. Overcoming challenges of treating inflammatory bowel disease in pregnancy. Expert Rev Clin Immunol. 2016 Aug; 12: (8)871-8.
    View PubMed
  44. Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K, Whitehead D, Hudesman D, Lukin D, Swaminath A, Shmidt E, Wang S, Boland BS, Chang JT, Kane S, Siegel CA, Loftus EV, Sandborn WJ, Sands BE, Colombel JF. The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium. Am J Gastroenterol. 2016 Aug; 111 (8):1147-55 Epub 2016 June 14
    View PubMed
  45. Sheibani S, Cohen R, Kane S, Dubinsky M, Church JA, Mahadevan U. The Effect of Maternal Peripartum Anti-TNFalpha Use on Infant Immune Response. Dig Dis Sci. 2016 Jun; 61 (6):1622-7 Epub 2016 Jan 02
    View PubMed
  46. Feagins LA, Kane SV. Caring for Women with Inflammatory Bowel Disease. Gastroenterol Clin North Am. 2016 Jun; 45: (2)303-15.
    View PubMed
  47. Kane S. IBD: Assisted reproductive technology less successful in ulcerative colitis. Nat Rev Gastroenterol Hepatol 2016 Jun; 13 (6):318-20 Epub 2016 May 05
    View PubMed
  48. Martin J, Kane SV, Feagins LA. Fertility and Contraception in Women With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2016 Feb; 12 (2):101-9
    View PubMed
  49. Tabibian JH, Yang JD, Baron TH, Kane SV, Enders FB, Gostout CJ. Weekend Admission for Acute Cholangitis Does Not Adversely Impact Clinical or Endoscopic Outcomes. Dig Dis Sci. 2016 Jan; 61 (1):53-61 Epub 2015 Sept 21
    View PubMed
  50. Fairchild EM, Lambert KL, Talley MI, Gleason A, Wengert H, Bohlen D, Elpert L, Bryant-Sendek D, Larson MV, Majka AJ, Kane SV. Cross-Site Scheduling of Endoscopic Procedures Improves Efficiency While Maintaining Patient Safety. J Healthc Qual. 2016 Jan-Feb; 38: (1)24-33.
    View PubMed
  51. Herman ML, Kane SV. Treatment Nonadherence in Inflammatory Bowel Disease: Identification, Scope, and Management Strategies. Inflamm Bowel Dis. 2015 Dec; 21 (12):2979-84
    View PubMed
  52. Sifuentes H, Kane S. Monitoring for Extra-Intestinal Cancers in IBD. Curr Gastroenterol Rep. 2015 Nov; 17 (11):42
    View PubMed
  53. Rosenblatt E, Kane S. Sex-Specific Issues in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2015 Sep; 11 (9):592-601
    View PubMed
  54. Beery RM, Kane SV. Management of Crohn's disease in pregnancy. Br J Hosp Med (Lond). 2015 Aug; 76: (8)455-63.
    View PubMed
  55. Moon W, Pestana L, Becker B, Loftus EV Jr, Hanson KA, Bruining DH, Tremaine WJ, Kane SV. Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice. Aliment Pharmacol Ther. 2015 Aug; 42 (4):428-40 Epub 2015 June 17
    View PubMed
  56. Tabibian A, Tabibian JH, Beckman LJ, Raffals LL, Papadakis KA, Kane SV. Predictors of health-related quality of life and adherence in Crohn's disease and ulcerative colitis: implications for clinical management. Dig Dis Sci. 2015 May; 60 (5):1366-74 Epub 2015 Jan 06
    View PubMed
  57. Chaudrey KH, Kane SV. Safety of Immunomodulators and Anti-TNF Therapy in Pregnancy. Curr Treat Options Gastroenterol. 2015 Mar; 13: (1)77-89.
    View PubMed
  58. Francis DL, Kane SV, Prabhakar S, Petersen BT. Validation of a multidisciplinary infrastructure to capture adverse events in a high-volume endoscopy unit. Clin Gastroenterol Hepatol. 2015 Feb; 13: (2)221-227.e1.
    View PubMed
  59. Hashash JG, Kane S. Pregnancy and Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2015 Feb; 11 (2):96-102
    View PubMed
  60. Horst S, Kane S. The use of biologic agents in pregnancy and breastfeeding. Gastroenterol Clin North Am. 2014 Sep; 43 (3):495-508 Epub 2014 July 05
    View PubMed
  61. Kane SV, Jaganathan S, Bedenbaugh AV, Palmer L, Schwartz DA. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease. Curr Med Res Opin. 2014 Sep; 30 (9):1821-6 Epub 2014 June 02
    View PubMed
  62. Vrabie R, Kane S. Noninvasive Markers of Disease Activity in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2014 Sep; 10 (9):576-84
    View PubMed
  63. De Felice KM, Kane SV. Inflammatory bowel disease in women of reproductive age. Expert Rev Gastroenterol Hepatol. 2014 May; 8(4):417-25. Epub 2014 Mar 03.
    View PubMed
  64. Weber NK, Fidler JL, Keaveny TM, Clarke BL, Khosla S, Fletcher JG, Lee DC, Pardi DS, Loftus EV Jr, Kane SV, Barlow JM, Murthy NS, Becker BD, Bruining DH. Validation of a CT-derived method for osteoporosis screening in IBD patients undergoing contrast-enhanced CT enterography. Am J Gastroenterol. 2014 Mar; 109 (3):401-8 Epub 2014 Jan 21
    View PubMed
  65. Singh S, Nagpal SJ, Murad MH, Yadav S, Kane SV, Pardi DS, Talwalkar JA, Loftus EV Jr. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014 Feb; 12 (2):210-8 Epub 2013 May 02
    View PubMed
  66. Ludvigsson JF, Bergquist A, Ajne G, Kane S, Ekbom A, Stephansson O. A population-based cohort study of pregnancy outcomes among women with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2014 Jan; 12(1):95-100.e1. Epub 2013 Jul 23
    View PubMed
  67. Marchioni Beery R, Kane S. Current approaches to the management of new-onset ulcerative colitis. Clin Exp Gastroenterol. 2014; 7:111-32 Epub 2014 May 09
    View PubMed
  68. Haq O, Ali T, Madhoun MF, Kane SV. Physician knowledge regarding concomitant antibiotic and oral contraceptive use in patients with IBD. Gastroenterol. Hepatol. 2014; 10(5):302-6.
  69. Kane SV, Neis B, Becker BD, Bruining D, Faubion WA, Kisiel J, Loftus EV Jr, Pardi D, Raffals L, Schroeder K, Tremaine WJ. Letter: Effectiveness of split-dose certolizumab pegol for Crohn's disease. Aliment Pharmacol Ther 2013 Dec; 38 (11-12):1412
    View PubMed
  70. Kane SV. Inflammatory bowel disease, women, and pregnancy. Gastroenterol Hepatol (N Y). 2013 Nov; 9 (11):741-3
    View PubMed
  71. McCurdy JD, Loftus EV Jr, Tremaine WJ, Smyrk TC, Bruining DH, Pardi DS, Raffals LE, Kisiel JB, Coelho-Prabhu N, Kane SV, Faubion WA, Papadakis KA. Cytomegalovirus infection of the ileoanal pouch: clinical characteristics and outcomes. Inflamm Bowel Dis. 2013 Oct; 19 (11):2394-9
    View PubMed
  72. Abraham NS, Richardson P, Castillo D, Kane SV. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013 Oct; 11(10):1281-7. Epub 2013 Jun 19.
    View PubMed
  73. Yarur A, Kane SV. Update on pregnancy and breastfeeding in the era of biologics. Dig Liver Dis. 2013 Oct; 45(10):787-94. Epub 2013 Mar 06.
    View PubMed
  74. Singh S, Kumar N, Loftus EV Jr, Kane SV. Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics. Inflamm Bowel Dis. 2013 Mar-Apr; 19 (4):864-72
    View PubMed
  75. Neis B, Hart P, Chandran V, Kane S. Mucosal schwann cell hamartoma of the colon in a patient with ulcerative colitis. Gastroenterol Hepatol (N Y). 2013 Mar; 9(3):183-5.
    View PubMed
  76. Hodgkins P, Yen L, Yarlas A, Karlstadt R, Solomon D, Kane S. Impact of MMX(R) mesalamine on improvement and maintenance of health-related quality of life in patients with ulcerative colitis. Inflamm Bowel Dis. 2013 Feb; 19(2):386-96.
    View PubMed
  77. Samuel S, Bruining DH, Loftus EV Jr, Thia KT, Schroeder KW, Tremaine WJ, Faubion WA, Kane SV, Pardi DS, de Groen PC, Harmsen WS, Zinsmeister AR, Sandborn WJ. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol. 2013 Jan; 11: (1)49-54.e1.
    View PubMed
  78. Kane S, Leighton J, Kefalas C, Cohen L, Katz P, Rizk M, Pike I, Lashner B, Ho I, Pochapin M, Seabrook M, Greenwald D, Demarco D, Johnson D. Quality commitment: the newly established American College of Gastroenterology Quality Council to meet the needs of clinical gastroenterology. Am J Gastroenterol. 2013 Jan; 108(1):7-9.
    View PubMed
  79. Kane SV, Horst S, Sandborn WJ, Becker B, Neis B, Moscandrew M, Hanson KA, Tremaine WJ, Bruining DH, Faubion WA, Pardi DS, Harmsen WS, Zinsmeister AR, Loftus EV. Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience. Inflamm Bowel Dis. 2012 Dec; 18 (12):2203-8 Epub 2012 Mar 14
    View PubMed
  80. Kane S. Establishing an inflammatory bowel disease practice in an accountable world. Clin Gastroenterol Hepatol. 2012 Dec; 10(12):1301-4.
    View PubMed
  81. Horst SN, Kane S. Multi-Matrix System (MMX(R)) mesalamine for the treatment of mild-to-moderate ulcerative colitis. Expert Opin Pharmacother. 2012 Oct; 13(15):2225-32. Epub 2012 Sep 13.
    View PubMed
  82. Kane S. What physicians don't know about patient dietary beliefs and behavior can make a difference. Expert Rev Gastroenterol Hepatol. 2012 Sep; 6(5):545-7.
    View PubMed
  83. Bernick SJ, Kane S. Drug transfer to the fetus and to the breastfeeding infant: what do we know? Curr Drug Deliv. 2012 Jul; 9(4):350-5.
    View PubMed
  84. Abraham BP, Kane S. Fecal markers: calprotectin and lactoferrin. Gastroenterol Clin North Am. 2012 Jun; 41(2):483-95. Epub 2012 Feb 16.
    View PubMed
  85. Solomon D, Yarlas A, Hodgkins P, Karlstadt R, Yen L, Kane S. The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients. Aliment Pharmacol Ther. 2012 Jun; 35(12):1386-96. Epub 2012 Apr 27.
    View PubMed
  86. Kane S, Katz S, Jamal MM, Safdi M, Dolin B, Solomon D, Palmen M, Barrett K. Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis. Inflamm Bowel Dis. 2012 Jun; 18 (6):1026-33 Epub 2011 Aug 11
    View PubMed
  87. Kane S, Becker B, Harmsen WS, Kurian A, Morisky DE, Zinsmeister AR. Use of a screening tool to determine nonadherent behavior in inflammatory bowel disease. Am J Gastroenterol. 2012 Feb; 107(2):154-60.
    View PubMed
  88. Grigg EL, Kane S, Katz S. Mimicry and deception in inflammatory bowel disease and intestinal behcet disease. Gastroenterol Hepatol (N Y). 2012 Feb; 8 (2):103-12
    View PubMed
  89. Ford AC, Khan KJ, Sandborn WJ, Kane SV, Moayyedi P. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011 Dec; 106(12):2070-7; quiz 2078. Epub 2011 Sep 06.
    View PubMed
  90. Wasan SK, Kane SV. Adalimumab for the treatment of inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2011 Dec; 5(6):679-84.
    View PubMed
  91. Lahiff C, Kane S, Moss AC. Drug development in inflammatory bowel disease: the role of the FDA. Inflamm Bowel Dis. 2011 Dec; 17(12):2585-93. Epub 2011 Apr 11.
    View PubMed
  92. Kane SV, Sumner M, Solomon D, Jenkins M. Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database. Dig Dis Sci. 2011 Dec; 56 (12):3463-70 Epub 2011 Aug 31
    View PubMed
  93. Kowalczyk R, Kane S. Inflammatory Bowel Disease: A Primary Care Primer. Consultant. 2011 Oct; 51(10):713-8.
  94. Feagins LA, Holubar SD, Kane SV, Spechler SJ. Current strategies in the management of intra-abdominal abscesses in Crohn's disease. Clin Gastroenterol Hepatol. 2011 Oct; 9(10):842-50. Epub 2011 May 05.
    View PubMed
  95. Kane SV. Preparing for biologic or immunosuppressant therapy. Gastroenterol Hepatol (N Y). 2011 Aug; 7 (8):544-6
    View PubMed
  96. Flynn A, Kane S. Mucosal healing in Crohn's disease and ulcerative colitis: what does it tell us? Curr Opin Gastroenterol. 2011 Jul; 27(4):342-5.
    View PubMed
  97. Beaulieu DB, Kane S. Inflammatory bowel disease in pregnancy. World J Gastroenterol. 2011 Jun 14; 17(22):2696-701.
    View PubMed
  98. Beaulieu DB, Kane S. Inflammatory bowel disease in pregnancy. Gastroenterol Clin North Am. 2011 Jun; 40(2):399-413, ix. Epub 2011 Apr 06.
    View PubMed
  99. Thia KT, Loftus EV Jr, Pardi DS, Kane SV, Faubion WA, Tremaine WJ, Schroeder KW, Harmsen SW, Zinsmeister AR, Sandborn WJ. Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflamm Bowel Dis. 2011 Jun; 17 (6):1257-64 Epub 2010 Sept 27
    View PubMed
  100. Levesque BG, Kane SV. Searching for the delta: 5-aminosalicylic Acid therapy for Crohn's disease. Gastroenterol Hepatol (N Y). 2011 May; 7(5):295-301.
    View PubMed
  101. Ford AC, Achkar JP, Khan KJ, Kane SV, Talley NJ, Marshall JK, Moayyedi P. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr; 106(4):601-16. Epub 2011 Mar 15.
    View PubMed
  102. Ford AC, Kane SV, Khan KJ, Achkar JP, Talley NJ, Marshall JK, Moayyedi P. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr; 106(4):617-29. Epub 2011 Mar 15.
    View PubMed
  103. Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, Kane SV, Sandborn WJ, Ullman TA, Moayyedi P, American College of Gastroenterology IBD Task Force. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011 Apr; 106 Suppl 1:S2-25; quiz S26.
    View PubMed
  104. Levesque BG, Kane SV. IBD: measuring what counts-safety of IBD medications in pregnancy. Nat Rev Gastroenterol Hepatol. 2011 Mar; 8 (3):126-8 Epub 2011 Feb 08
    View PubMed
  105. Holubar SD, Kane S. Prevention and treatment of postproctectomy infertility. Semin. Colon Rectal Surg. 2011; 22(4):249-54.
  106. Kane S. Preparing the patient for immunosuppressive therapy. Curr Gastroenterol Rep. 2010 Dec; 12 (6):502-6
    View PubMed
  107. Swoger JM, Loftus EV Jr, Tremaine WJ, Faubion WA, Pardi DS, Kane SV, Hanson KA, Harmsen WS, Zinsmeister AR, Sandborn WJ. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis. 2010 Nov; 16 (11):1912-21
    View PubMed
  108. Kane SV, Robinson A. Review article: understanding adherence to medication in ulcerative colitis - innovative thinking and evolving concepts. Aliment Pharmacol Ther. 2010 Nov; 32(9):1051-8. Epub 2010 Sep 03.
    View PubMed
  109. Bernick SJ, Kane S. Insight into the widespread problem of nonadherence to therapy in ulcerative colitis patients. Expert Rev Clin Immunol. 2010 Jul; 6(4):677-82.
    View PubMed
  110. Afif W, Loftus EV Jr, Faubion WA, Kane SV, Bruining DH, Hanson KA, Sandborn WJ. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010 May; 105(5):1133-9. Epub 2010 Feb 09.
    View PubMed
  111. Chang JY, Marks RS, Nagorney DM, Sanderson SO, Kane S. Ulcerative colitis, infliximab, and hepatic epithelioid hemangioendothelioma: who is to blame? Case Report. Therap Adv Gastroenterol. 2010 May; 3 (3):203-6
    View PubMed
  112. Travis AC, Katz PO, Kane SV. Mentoring in gastroenterology. Am J Gastroenterol. 2010 May; 105(5):970-2.
    View PubMed
  113. Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, Dunnmon P, Ramsey D, Kane S. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology. 2010 Apr; 138(4):1286-96, 1296.e1-3. Epub 2010 Jan 11.
    View PubMed
  114. Rubin DT, Dubinsky MC, Panaccione R, Siegel CA, Binion DG, Kane SV, Hopper J. The impact of ulcerative colitis on patients' lives compared to other chronic diseases: a patient survey. Dig Dis Sci. 2010 Apr; 55(4):1044-52. Epub 2009 Sep 04.
    View PubMed
  115. Kane S. Does treatment schedule matter? Once daily versus divided doses of 5-ASAs. Dig Dis. 2010; 28(3):478-82. Epub 2010 Sep 30.
    View PubMed
  116. Bernick SJ, Kane S. Improving adherence in inflammatory bowel disease. Pract Gastroenterol. 2010; 34(2):17-22.
  117. Kane S. A 38-year-old with recurrent colitis. Is it noncompliance? Clin Gastroenterol Hepatol. 2009 Nov; 7(11):1164-7. Epub 2009 Jul 01.
    View PubMed
  118. Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients. Adv Ther. 2009 Oct; 26 (10):936-46 Epub 2009 Oct 16
    View PubMed
  119. Moscandrew M, Kane S. Inflammatory bowel diseases and management considerations: fertility and pregnancy. Curr Gastroenterol Rep. 2009 Oct; 11 (5):395-9
    View PubMed
  120. Moscandrew M, Mahadevan U, Kane S. General health maintenance in IBD. Inflamm Bowel Dis. 2009 Sep; 15 (9):1399-409
    View PubMed
  121. Afif W, Leighton JA, Hanauer SB, Loftus EV Jr, Faubion WA, Pardi DS, Tremaine WJ, Kane SV, Bruining DH, Cohen RD, Rubin DT, Hanson KA, Sandborn WJ. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15 (9):1302-7
    View PubMed
  122. Kane S, Ford J, Cohen R, Wagner C. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol. 2009 Aug; 43(7):613-6.
    View PubMed
  123. Kane S, Lu F, Kornbluth A, Awais D, Higgins PD. Controversies in mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2009 May; 15 (5):796-800
    View PubMed
  124. Kane SV, Accortt NA, Magowan S, Brixner D. Predictors of persistence with 5-aminosalicylic acid therapy for ulcerative colitis. Aliment Pharmacol Ther. 2009 Apr 15; 29(8):855-62. Epub 2009 Jan 17.
    View PubMed
  125. Okoro NI, Kane SV. Gender-related issues in the female inflammatory bowel disease patient. Expert Rev Gastroenterol Hepatol. 2009 Apr; 3(2):145-54.
    View PubMed
  126. Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol. 2009 Jan; 104(1):228-33.
    View PubMed
  127. Kane S. Endoscopic healing should be a goal for everyone with ulcerative colitis. Inflamm Bowel Dis. 2008 Nov 4 Epub 2008 Nov 04
    View PubMed
  128. Kane S. What are the minimal requirements for a diagnosis of inflammatory bowel disease? Inflamm Bowel Dis. 2008 Oct; 14 Suppl 2:S148-9
    View PubMed
  129. Hutfless S, Fireman B, Kane S, Herrinton LJ. Screening differences and risk of cervical cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2008 Sep 1; 28(5):598-605. Epub 2008 Jun 28.
    View PubMed
  130. Kane SV, Loftus EV Jr, Dubinsky MC, Sederman R. Disease perceptions among people with Crohn's disease. Inflamm Bowel Dis. 2008 Aug; 14 (8):1097-101
    View PubMed
  131. Kane S. Abnormal Pap smears in inflammatory bowel disease. Inflamm Bowel Dis. 2008 Aug; 14 (8):1158-60
    View PubMed
  132. Kane SV, Reddy D. Hormonal replacement therapy after menopause is protective of disease activity in women with inflammatory bowel disease. Am J Gastroenterol. 2008 May; 103(5):1193-6. Epub 2008 Jan 02.
    View PubMed
  133. Quin A, Kane S, Ulitsky O. A case of fistulizing Crohn's disease and erythema nodosum managed with adalimumab. Nat Clin Pract Gastroenterol Hepatol. 2008 May; 5(5):278-81. Epub 2008 Mar 25.
    View PubMed
  134. Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci. 2008 Apr; 53 (4):1020-4 Epub 2007 Oct 13
    View PubMed
  135. Shugart YY, Silverberg MS, Duerr RH, Taylor KD, Wang MH, Zarfas K, Schumm LP, Bromfield G, Steinhart AH, Griffiths AM, Kane SV, Barmada MM, Rotter JI, Mei L, Bernstein CN, Bayless TM, Langelier D, Cohen A, Bitton A, Rioux JD, Cho JH, Brant SR. An SNP linkage scan identifies significant Crohn's disease loci on chromosomes 13q13.3 and, in Jewish families, on 1p35.2 and 3q29. Genes Immun. 2008 Mar; 9(2):161-7. Epub 2008 Jan 31.
    View PubMed
  136. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008 Mar; 103(3):631-6. Epub 2007 Oct 17.
    View PubMed
  137. Kane S, Holderman W, Jacques P, Miodek T. Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial. Patient Prefer Adherence. 2008 Feb 2; 2:253-8 Epub 2008 Feb 02
    View PubMed
  138. Selby L, Kane S, Wilson J, Balla P, Riff B, Bingcang C, Hoellein A, Pande S, de Villiers WJ. Receipt of preventive health services by IBD patients is significantly lower than by primary care patients. Inflamm Bowel Dis. 2008 Feb; 14(2):253-8.
    View PubMed
  139. Kane SV. Patient Adherence in IBD. Primary Care Quartlerly. 2008; 12(1):39-44.
  140. Kane SV, Brixner D, Rubin DT, Sewitch MJ. The challenge of compliance and persistence: focus on ulcerative colitis. J Manag Care Pharm. 2008 Jan; 14(1 Suppl A):s2-12; quiz s13-5.
    View PubMed
  141. Kane SV. Strategies to improve adherence and outcomes in patients with ulcerative colitis. Drugs. 2008; 68 (18):2601-9
    View PubMed
  142. Okoro N, Kane S. Abnormal cervical cytology and inflammatory bowel disease: Impact of immunosuppression. Pract Gastroenterol. 2008; 32(11):33-4, 36.
  143. Mahadevan U, Sandborn WJ, Li DK, Hakimian S, Kane S, Corley DA. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology. 2007 Oct; 133(4):1106-12. Epub 2007 Jul 25.
    View PubMed
  144. Kane SV. Overcoming adherence issues in ulcerative colitis. Gastroenterol Hepatol (N Y). 2007 Oct; 3 (10):795-9
    View PubMed
  145. Dassopoulos T, Nguyen GC, Bitton A, Bromfield GP, Schumm LP, Wu Y, Elkadri A, Regueiro M, Siemanowski B, Torres EA, Gregory FJ, Kane SV, Harrell LE, Franchimont D, Achkar JP, Griffiths A, Brant SR, Rioux JD, Taylor KD, Duerr RH, Silverberg MS, Cho JH, Steinhart AH. Assessment of reliability and validity of IBD phenotyping within the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) IBD Genetics Consortium (IBDGC). Inflamm Bowel Dis. 2007 Aug; 13(8):975-83.
    View PubMed
  146. Silverberg MS, Duerr RH, Brant SR, Bromfield G, Datta LW, Jani N, Kane SV, Rotter JI, Philip Schumm L, Hillary Steinhart A, Taylor KD, Yang H, Cho JH, Rioux JD, Daly MJ, NIDDK IBD Genetics Consortium. Refined genomic localization and ethnic differences observed for the IBD5 association with Crohn's disease. Eur J Hum Genet. 2007 Mar; 15(3):328-35. Epub 2007 Jan 10.
    View PubMed
  147. Parekh N, Kane S. The pregnant IBD patient: what every gastroenterologist should consider. Pract Gastroenterol. 2007; 31(2):17-28.
  148. Zisman TL, Kane SV. Current and future therapies for inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2007; 1(1):89-100.
  149. Kane SV. The complexity of compliance and persistence in ulcerative colitis. Gastroenterol. Hepatol. 2007; 3(9 Suppl 28):3-10.
  150. Kane S. Urogenital complications of Crohn's disease. Am J Gastroenterol. 2006 Dec; 101(12 Suppl):S640-3.
    View PubMed
  151. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006 Oct 17; 145(8):557-63.
    View PubMed
  152. Kane S, Dixon L. Adherence rates with infliximab therapy in Crohn's disease. Aliment Pharmacol Ther. 2006 Oct 1; 24(7):1099-103.
    View PubMed
  153. Kane S, Reddy D. Guidelines do help change behavior in the management of osteoporosis by gastroenterologists. Am J Gastroenterol. 2006 Aug; 101(8):1841-4. Epub 2006 Jun 30.
    View PubMed
  154. Reddy D, Siegel CA, Sands BE, Kane S. Possible association between isotretinoin and inflammatory bowel disease. Am J Gastroenterol. 2006 Jul; 101(7):1569-73.
    View PubMed
  155. Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006 Jul; 131(1):283-311.
    View PubMed
  156. Mahadevan U, Kane S. American gastroenterological association institute medical position statement on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006 Jul; 131(1):278-82.
    View PubMed
  157. Nguyen GC, Torres EA, Regueiro M, Bromfield G, Bitton A, Stempak J, Dassopoulos T, Schumm P, Gregory FJ, Griffiths AM, Hanauer SB, Hanson J, Harris ML, Kane SV, Orkwis HK, Lahaie R, Oliva-Hemker M, Pare P, Wild GE, Rioux JD, Yang H, Duerr RH, Cho JH, Steinhart AH, Brant SR, Silverberg MS. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol. 2006 May; 101(5):1012-23.
    View PubMed
  158. Kane SV. Asacol -- a review focusing on ulcerative colitis. US Gastroenterology Review. 2006 Mar:22-5.
  159. Keswani RN, Sauk J, Kane SV. Factitious diarrhea masquerading as refractory celiac disease. South Med J. 2006 Mar; 99(3):293-5.
    View PubMed
  160. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006 Mar 1; 23(5):577-85.
    View PubMed
  161. Blair SA, Kane SV, Clayburgh DR, Turner JR. Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. Lab Invest. 2006 Feb; 86(2):191-201.
    View PubMed
  162. Kane S. Colon lesions: pathology specific to women. Gastrointest Endosc Clin N Am. 2006 Jan; 16(1):165-73.
    View PubMed
  163. Loftus EV, Kane SV, Lichtensetein GR, Sandborn WJ. Contemporary management of ulcerative colitis: the patient's perspective. Gastroenterology & Hepatology. 2006; 2(9):4-15.
  164. Lichtenstein GR, Kane SV, Velayos FS. Short and long term benefits of successful mucosal healing and patient compliance in ulcerative colitis. Gastroenterology & Hepatology. 2006; 2(12):S1-10.
  165. Kane SV. Another biologic for Crohn's disease: not so fast. Evid Based Gastroenterol. 2006; 7(2):5-6.
  166. Kane SV. Best of DDW 2006. Gastroenterology & Hepatology. 2006; 2(7):521-4.
  167. Giannini EG, Kane SV, Testa R, Savarino V. 5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for 'best evidence'? Dig Liver Dis. 2005 Oct; 37(10):723-31.
    View PubMed
  168. Sauk J, Kane S. The use of medications for inflammatory bowel disease during pregnancy and nursing. Expert Opin Pharmacother. 2005 Sep; 6(11):1833-9.
    View PubMed
  169. Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, Binion DG. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005 Mar 15; 21(6):733-8.
    View PubMed
  170. Kane S. Gender issues in the management of irritable bowel syndrome. Int J Fertil Womens Med. 2005 Mar-Apr; 50(2):79-82.
    View PubMed
  171. Kane SV, DeVos M, Riley S, Frieri G, Mittman U. Compliance with IBD therapy: facts, concerns and ways forward. Rev Gastroenterol Disord. 2005; 5(2):101-5.
  172. Kane S, Lemieux N. The role of breastfeeding in postpartum disease activity in women with inflammatory bowel disease. Am J Gastroenterol. 2005 Jan; 100(1):102-5.
    View PubMed
  173. Kane SV, Flicker M, Katz-Nelson F. Tobacco use is associated with accelerated clinical recurrence of Crohn's disease after surgically induced remission. J Clin Gastroenterol. 2005 Jan; 39(1):32-5.
    View PubMed
  174. Kane SV. Controversies in IBD case management. Clinician. 2005; 23(1).
  175. Kane SV. Gender issues in inflammatory bowel diseases. Women's Health. 2005; 1(3):401-8.
  176. Sandborn WJ, Hanauer S, Loftus EV Jr, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004 Oct; 99(10):1984-9.
    View PubMed
  177. Kane S, Cohen SM, Hart J. Acute sinusoidal obstruction syndrome after 6-thioguanine therapy for Crohn's disease. Inflamm Bowel Dis. 2004 Sep; 10(5):652-4.
    View PubMed
  178. Kane S, Kisiel J, Shih L, Hanauer S. HLA disparity determines disease activity through pregnancy in women with inflammatory bowel disease. Am J Gastroenterol. 2004 Aug; 99(8):1523-6.
    View PubMed
  179. Lichtenstein GR, Cuffari C, Kane SV, Hanauer S, Present DH. Maintaining remissions across the lifespan: a roundtable discussion with Crohn's disease experts. Inflamm Bowel Dis. 2004 Jul; 10 Suppl 2:S11-21.
    View PubMed
  180. Lichtenstein GR, Hanauer SB, Kane SV, Present DH. Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease. Inflamm Bowel Dis. 2004 Jul; 10 Suppl 2:S2-10.
    View PubMed
  181. Baker DE, Kane S. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis. Rev Gastroenterol Disord. 2004 Spring; 4(2):86-91.
    View PubMed
  182. Loftus EV Jr, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2004 Jan 15; 19 (2):179-89
    View PubMed
  183. Kane SV. Adherence issues in the patient with inflammatory bowel disease. Pract Gastroenterol. 2004; 28(9):16-22.
  184. Kane SV. Managing the pregnant patient with inflammatory bowel disease. Pract Gastroenterol. 2004; 28(10):16-26.
  185. Kane SV. Breastfeeding and IBD: safety and management issues. Inflammatory Bowel Disease Monitor. 2004; 6(2):50-2.
  186. Kane SV, Borisov NN, Brixner D. Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with risedronate or alendronate: a retrospective cohort study. Am J Manag Care. 2004; 10:S216-26.
  187. Kane SV. Another reason why immunomodulators are better than steroids: lack of asosciation with postoperative infections. Evid Based Gastroenterol. 2004; 5(1):26-7.
  188. Kane SV, Bjorkman DJ. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. Rev Gastroenterol Disord. 2003 Fall; 3(4):210-8.
    View PubMed
  189. Brant SR, Picco MF, Achkar JP, Bayless TM, Kane SV, Brzezinski A, Nouvet FJ, Bonen D, Karban A, Dassopoulos T, Karaliukas R, Beaty TH, Hanauer SB, Duerr RH, Cho JH. Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Inflamm Bowel Dis. 2003 Sep; 9(5):281-9.
    View PubMed
  190. Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanauer SB. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003 Jun; 98(6):1309-14.
    View PubMed
  191. Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol. 2003 May; 1(3):170-3.
    View PubMed
  192. Tuvlin JA, Kane SV. Novel therapies in the treatment of ulcerative colitis. Expert Opin Investig Drugs. 2003 Mar; 12(3):483-90.
    View PubMed
  193. Kane S. Inflammatory bowel disease in pregnancy. Gastroenterol Clin North Am. 2003 Mar; 32(1):323-40.
    View PubMed
  194. Kane SV. Some reassuring news for 6-MP users. Evid Based Gastroenterol. 2003; 4(3):100-1.
  195. Kane SV. Bugs as drugs: ready for the "mainstream"? Evid Based Gastroenterol. 2003; 4(4):135-6.
  196. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003 Jan; 114(1):39-43.
    View PubMed
  197. Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG. The effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther. 2002 Aug; 16(8):1509-17.
    View PubMed
  198. Kane S, Stone LJ, Ehrenpreis E. Thalidomide as "salvage" therapy for patients with delayed hypersensitivity response to infliximab: a case series. J Clin Gastroenterol. 2002 Aug; 35(2):149-50.
    View PubMed
  199. Kane S. Gender issues in the management of inflammatory bowel disease and irritable bowel syndrome. Int J Fertil Womens Med. 2002 May-Jun; 47(3):136-42.
    View PubMed
  200. Kane SV. Managing pregnancy in IBD. Inflammatory Bowel Disease Monitor. 2002; 4(1):1-12.
  201. Kane SV. Yet another steroid that we will learn to avoid: beclometasone dipropionate for ulcerative colitis. Evid Based Gastroenterol. 2002; 3(1):92-4.
  202. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001 Oct; 96(10):2929-33.
    View PubMed
  203. Kane SV. Novel therapies in the treatment of ulcerative colitis. Expert Opin Investig Drugs. 2001 Jul; 10(7):1223-9.
    View PubMed
  204. Kane SV. Non-steroidal anti-inflammatory drugs are associated with an increased risk of disease activity in inflammatory bowel disease. Evid Based Gastroenterol. 2001; 2(1):20-1.
  205. Kane SV. Growth hormone for Crohn's disease: not the new wonder drug. Evid Based Gastroenterol. 2001; 2(1):28-9.
  206. Kane SV. Is ursodiol protective against colorectal cancer in patients with ulcerative colitis and primary sclerosing cholangitis? Evid Based Gastroenterol. 2001; 2(2):70-1.
  207. Kane SV. A decreased murine content does not necessarily equate to improved efficacy in targeted biologics. Evid Based Gastroenterol. 2001; 2(3):115.
  208. Kane S. Caring for women with inflammatory bowel disease. J Gend Specif Med. 2001; 4(1):54-9.
    View PubMed
  209. Kane S, Brasitus T. Histoplasmosis capsulatum as a cause of lower gastrointestinal bleeding in common variable immunodeficiency. Dig Dis Sci. 2000 Nov; 45(11):2133-5.
    View PubMed
  210. Kane SV. Colorectal cancer surveillance of patients with ulcerative colitis is disorganized and inconsistent. Evid Based Gastroenterol. 2000; 1(1):20-1.
  211. Kane SV. Methotrexate appear efficacious and safe for maintenance in Crohn's disease. Evid Based Gastroenterol. 2000; 1(2):70-1.
  212. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology. 1999 Dec; 117(6):1271-7.
    View PubMed
  213. Kane S. Patient compliance and outcomes. Inflamm Bowel Dis. 1999 May; 5(2):134-7.
    View PubMed
  214. Kane SV, Sable K, Hanauer SB. The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. Am J Gastroenterol. 1998 Oct; 93(10):1867-72.
    View PubMed
  215. Lashner BA, Kane SV, Hanauer SB. Lack of association between oral contraceptive use and ulcerative colitis. Gastroenterology. 1990 Oct; 99(4):1032-6.
    View PubMed
  216. Lashner BA, Kane SV, Hanauer SB. Colon cancer surveillance in chronic ulcerative colitis: historical cohort study. Am J Gastroenterol. 1990 Sep; 85(9):1083-7.
    View PubMed
  217. Lashner BA, Kane SV, Hanauer SB. Lack of association between oral contraceptive use and Crohn's disease: a community-based matched case-control study. Gastroenterology. 1989 Dec; 97(6):1442-7.
    View PubMed
  218. Lashner BA, Heidenreich PA, Su GL, Kane SV, Hanauer SB. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology. 1989 Aug; 97(2):255-9.
    View PubMed
PST-20224637